Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Unicenta
- Development stage
- Phase 3
- Lead developer
- Unimed Pharm
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
Unicenta is an investigational pharmaceutical drug developed by Unimed Pharmaceuticals. It is an injectable placental extract being studied for the treatment of menopausal syndrome. Clinical trials have shown it to be non-inferior to Melsmon, another placental extract, in improving menopausal symptoms as measured by the Kupperman index. Its therapeutic effects are believed to stem from its rich composition of biological components, including vitamins, minerals, proteins, peptides, cytokines, and hormones.
Beyond the preview
Go deeper on Unicenta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Unicenta.